Linear Clinical Research

Running trials

• Recruiting

  TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

  NCT07713732· Phase 1· Source

• Recruiting

  A Study of ARC-02 in B-cell NHL

  NCT07691606· Phase 1· Source

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Source

• Recruiting

  Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

  NCT07249905· Phase 1/2· Source

• Recruiting

  A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants

  NCT07532655· Phase 1· Source

• Recruiting

  Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease

  NCT07285122· Phase 1· Source

• Recruiting

  Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

  NCT07334119· Phase 1· Source

• Recruiting

  A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

  NCT07244705· Phase 1/2· Source

• Recruiting

  A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  NCT07008118· Phase 1· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· Phase 3· Source

• Recruiting

  A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

  NCT06917742· Phase 1· Source

• Recruiting

  BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

  NCT06756932· Phase 1· Source

• Recruiting

  A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

  NCT06697184· Phase 1/2· Source

• Active, not recruiting

  A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

  NCT06679985· Phase 2· Source

• Recruiting

  ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

  NCT06597721· Phase 1· Source

• Recruiting

  A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  NCT06465069· Phase 1· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Source

• Recruiting

  Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  NCT06343402· Phase 1· Source

• Active, not recruiting

  Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

  NCT06205628· Phase 1· Source

• Recruiting

  Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  NCT06162221· Phase 1/2· Source

• Recruiting

  A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  NCT06179160· Phase 1· Source

• Recruiting

  Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

  NCT05862012· Phase 1· Source

• Recruiting

  IKS014 in Advanced Solid Tumors That Express HER2

  NCT05872295· Phase 1· Source

• Active, not recruiting

  Study to Assess SLN124 in Patients With Polycythemia Vera

  NCT05499013· Phase 1/2· Source

• Recruiting

  Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

  NCT05320198· Phase 1/2· Source

• Recruiting

  A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  NCT05006716· Phase 1/2· Source

• Active, not recruiting

  Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

  NCT04956640· Phase 1/2· Source

• Recruiting

  A Study of BGB-11417 in Participants With Myeloid Malignancies

  NCT04771130· Phase 1/2· Source

• Active, not recruiting

  Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

  NCT04662255· Phase 3· Source

• Recruiting

  Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

  NCT04665206· Phase 1/2· Source

• Recruiting

  Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

  NCT04683250· Phase 1/2· Source

• Active, not recruiting

  Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

  NCT04603001· Phase 1· Source

• Recruiting

  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  NCT04585750· Phase 1/2· Source

• Active, not recruiting

  A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

  NCT04188548· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer7 recruiting
• Colorectal cancer4 recruiting
• Follicular lymphoma4 recruiting
• Mantle cell lymphoma4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Head and neck cancer3 recruiting
• Ovarian cancer3 recruiting
• Bladder cancer2 recruiting
• Endometrial cancer2 recruiting
• Gastric and esophageal cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Mesothelioma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Pancreatic cancer2 recruiting
• Prostate cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Acute myeloid leukemia1 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• COPD1 recruiting
• Hodgkin lymphoma1 recruiting
• Lupus (SLE)1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Trial of HRS-1893 in Healthy Volunteers

  NCT07033455· Early phase 1· Source

• Terminated

  A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  NCT06585488· Phase 1· Source

• Completed

  A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

  NCT06326060· Phase 2· Source

• Terminated

  A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· Phase 1· Source

• Completed

  Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

  NCT05583552· Phase 2· Source

• Terminated

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· Phase 1· Source

• Completed

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

  NCT04242199· Phase 1· Source

• Completed

  IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

  NCT04109456· Phase 1· Source

• Completed

  Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

  NCT04215978· Phase 1· Source

• Completed

  A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

  NCT03740529· Phase 1/2· Source

• Completed

  A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma

  NCT03331731· Phase 2· Source